CeriBell, Inc. (CBLL) Stock Price & Analysis
CeriBell, Inc. (CBLL) closed at USD 27.22 on Wednesday, October 28, 2026, up 0.00% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 27.22; the Oct 28, 2026 session ranged USD 26.81–27.6 on volume of 742,942 shares. Market capitalization is $1.04B, with a 52-week range of USD 10.85–28.11 (NMS). Source: Nexqual, retrieved October 29, 2026 at 11:26 UTC.
Also available as compact Markdown for AI agents: nexqual.com/CBLL.md
Key facts (CBLL)
- Last four reported quarters (through Jun 30, 2026): revenue $102M, net income -$66.0M (-64.7% margin), free cash flow -$54.7M (SEC filings).
- Analysts: Buy (mean 1.88 on a 1–5 scale) (8 analysts), mean target USD 28.57 (range 24–33).
- Total return with dividends: 1Y +126.3% vs S&P 500 +13.6%; 5Y +8.9% vs S&P 500 +79.8%.
- Next earnings: 2026-11-03, EPS estimate USD -0.52, revenue estimate $29.2M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (CBLL)
| USD | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|
| Revenue | $45.2M | $65.4M | $89.1M | $102M |
| Gross profit | $38.2M | $56.8M | $78.3M | — |
| Operating income | -$30.0M | -$39.7M | -$58.4M | -$70.0M |
| Net income | -$29.5M | -$40.5M | -$53.4M | -$66.0M |
| EPS (diluted) | -$5.56 | -$3.39 | -$1.46 | — |
| Free cash flow | -$30.1M | -$36.4M | -$41.6M | -$54.7M |
| Gross margin | 84.4% | 86.7% | 87.9% | — |
| Operating margin | -66.4% | -60.7% | -65.6% | -68.6% |
| Net margin | -65.1% | -61.8% | -60.0% | -64.7% |
| Revenue growth | — | +44.7% | +36.1% | — |
| Cash + short-term investments | $34.5M | $194M | $159M | — |
| Total debt | — | $19.6M | $19.8M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (CBLL)
P/S 10.3x · EV/Sales 9.2x · P/B 8.1x · FCF yield -5.24% · Earnings yield -6.32% · Net cash $109M · EV $935M
Analysts (CBLL)
Consensus Buy (mean 1.88 on a 1–5 scale), 8 analysts; mean target USD 28.57 (low 24, high 33).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-02 | TD Cowen | Target raised | Buy | $29 → $33 |
| 2026-09-11 | BTIG | Reiterated | Buy | $30 |
| 2026-08-18 | BTIG | Target raised | Buy | $28 → $30 |
| 2026-08-11 | Canaccord Genuity | Target raised | Buy | $25 → $26 |
| 2026-08-11 | BTIG | Reiterated | Buy | $28 |
Total return (dividends reinvested) (CBLL)
| 1Y (from 2025-10-29) | 5Y (from 2024-10-07) | |
|---|---|---|
| Total return | +126.3% | +8.9% |
| S&P 500 (SPY) | +13.6% | +79.8% |
| Per year | +126.9% | +4.2% |
| Volatility (annualized) | 51.6% | 52.5% |
| Max drawdown | -30.5% (Jan 2026→Jul 2026) | -62.4% (Dec 2024→Sep 2025) |
CBLL earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| Aug 10, 2026 | Quarter ended Jun 30, 2026 | −$0.40 | −$0.46 | Beat +13.0% | +13.3% |
| May 11, 2026 | Quarter ended Mar 31, 2026 | −$0.38 | −$0.39 | Beat +2.6% | -17.1% |
| Feb 24, 2026 | Quarter ended Dec 31, 2025 | −$0.36 | −$0.41 | Beat +12.2% | -5.2% |
| Nov 4, 2025 | Quarter ended Sep 30, 2025 | −$0.37 | −$0.41 | Beat +9.8% | +3.9% |
| Aug 5, 2025 | — | — | — | — | -16.1% |
| May 8, 2025 | — | — | — | — | -0.2% |
| Feb 25, 2025 | — | — | — | — | -0.9% |
| Nov 12, 2024 | — | — | — | — | -3.5% |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).
CBLL recent SEC filings (last 120 days)
| Filed | Form | What it says |
|---|---|---|
| Aug 14, 2026 | Schedule 13G/A | TPG GP A, LLC, COULTER, JAMES G: 7.8% of shares, passive 5%+ holder (amended) |
| Aug 10, 2026 | 10-Q | Quarterly report · period ended Jun 30, 2026 |
| Aug 10, 2026 | 8-K | Quarterly results |
| Aug 6, 2026 | Schedule 13G/A | FMR LLC, Abigail P. Johnson: 15.0% of shares, passive 5%+ holder (amended) |
| Jul 30, 2026 | 8-K | Director or executive officer change, or pay arrangement “Effective July 28, 2026, the Board of Directors (the "Board") of CeriBell, Inc. (the "Company"), in order to achieve a more balanced membership among the classes of directors, accepted the resignation of William W. Burke as a Class I director and immediately elected him as a Class II director, and accepted the resignation of Joseph M. Taylor as a Class I director and immediately elected him as a Class III director. The resignations and re-elections of Mr. Burke and Mr. Taylor were effected solely to rebalance the…” |
| Jul 27, 2026 | Schedule 13G | BlackRock, Inc.: 5.0% of shares, passive 5%+ holder |
Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.
CBLL suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Supplier | Shenzhen Everwin Precision Technology | “In January 2022, we entered into a corporate supply agreement with Shenzhen Everwin Precision Technology Co., Ltd. ("Everwin China") for the supply of headbands on a purchase order basis.” |
Quoted from the company's 10-K filed Feb 24, 2026.
CBLL company outlook (results filed Aug 10, 2026)
- “Ceribell is raising its revenue guidance for the full year 2026 to a range of $114 million to $117 million, representing growth of approximately 28% to 31% over the Company's prior year revenue.”
- “This earnings release and the related attachments contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about, among other topics, our anticipated operating and financial performance, including financial guidance and projections; business plans, strategy, goals and prospects; and expectations for our products.”
Quoted word-for-word from the SEC 8-K results press release.
CBLL analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.52 | $-0.37 | −$0.15 | $29.2M | 5 |
| Next quarter (ends Dec 2026) | $-0.43 | $-0.34 | −$0.09 | $31.7M | 5 |
| Current fiscal year (ends Dec 2026) | $-1.96 | $-1.68 | −$0.28 | $115.5M | 5 |
| Next fiscal year (ends Dec 2027) | $-1.61 | $-1.10 | −$0.51 | $147.1M | 5 |
CBLL options: expected move
Options price a move of about ±14.2% (±$3.86) by Nov 20, 2026, which includes earnings on Nov 3, 2026. Over the last 8 reports the stock moved ±7.5% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 22 | 81.0% | ±14.2% |
| Dec 18, 2026 | 50 | 78.6% | ±23.1% |
| Mar 19, 2027 | 141 | 63.2% | ±30.3% |
| Jun 17, 2027 | 231 | 64.3% | ±38.9% |
30-day implied volatility 73.4% vs 53.3% realized over the last 30 trading days. Put/call ratio (volume) 1. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 29, 2026 at 11:26 UTC)
| Price | USD 27.22 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 27.22 |
| Open | USD 27.22 |
| Day Range | USD 26.81 – 27.6 |
| 52-Week Range | USD 10.85 – 28.11 |
| Volume | 742,942 shares |
| Market Cap | $1.04B |
| Exchange | NMS |
Technical Analysis (CBLL)
Nexqual's technical model rates CBLL "BUY" based on 5 bullish and 1 bearish signals across 127 daily candles, as of October 29, 2026 at 11:26 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 59.81 (neutral) |
| vs SMA50 | Above (USD 24.82) |
| MACD | 0.89 (positive) |
Analyst Ratings (CBLL)
Wall Street analysts rate CBLL "Buy" based on 8 analysts, with a mean price target of USD 28.57 (range USD 24–33), per Nexqual as of October 29, 2026 at 11:26 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 8 |
| Mean Target | USD 28.57 |
| High Target | USD 33 |
| Low Target | USD 24 |
| Buy / Hold / Sell | 8 / 0 / 0 |
Earnings (CBLL)
| Next Earnings Date | 2026-11-03 |
|---|---|
| EPS Estimate | USD -0.52 |
| Revenue Estimate | $29.16M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.4 vs est -0.46 ▲ beat |
| 2026-03-31 | USD -0.38 vs est -0.39 ▲ beat |
| 2025-12-31 | USD -0.36 vs est -0.41 ▲ beat |
| 2025-09-30 | USD -0.37 vs est -0.41 ▲ beat |
Source: Nexqual, October 29, 2026 at 11:26 UTC.
Financials & Fundamentals (CBLL)
| Total Revenue | $101.96M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +32.50% |
| Gross Margin | +88.90% |
| Operating Margin | -71.11% |
| Profit Margin | -64.73% |
| ROE | -43.93% |
| Debt / Equity | 0.17 |
| Current Ratio | 9.18 |
| Total Cash | $129.26M |
| Total Debt | $21.91M |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | -$54.72M (-53.7% of revenue) |
Source: Nexqual, October 29, 2026 at 11:26 UTC.
Financial Health Score (CBLL)
Nexqual rates CeriBell, Inc.'s overall financial health "Mixed" across five dimensions, as of October 29, 2026 at 11:26 UTC.
| Growth | Strong — Revenue +36% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 89%, operating -69% (last 4 quarters to Jun 2026, SEC) |
| Balance Sheet | Strong — $129M cash and investments vs $20M debt (Jun 2026, SEC), net cash |
| Cash Flow | Weak — FCF negative: -$55M (last 4 quarters to Jun 2026, SEC), burning cash |
| Efficiency | Critical — ROE -51%, ROA -39.7% (last 4 quarters, SEC) |
Ownership (CBLL)
| Insider Ownership | +11.84% |
|---|---|
| Institutional Ownership | +90.77% |
| Shares Outstanding | 38.38M |
| Float | 26.55M |
| Short % of Float | +8.61% |
Source: Nexqual, October 29, 2026 at 11:26 UTC.
Leadership (CBLL)
CeriBell, Inc. is led by Xingjuan Chao, Co-Founder, President, CEO & Director, per Nexqual as of October 29, 2026 at 11:26 UTC.
| Co-Founder, President, CEO & Director | Xingjuan Chao |
|---|---|
| Co-Founder, Chief Medical Advisor & Director | Josef Parvizi |
| Chief Financial Officer | Scott Blumberg |
| Chief Technology Officer | Raymond Woo |
| Senior Vice President of Marketing | Brian P. Price |
Major Backers & Investors (CBLL)
Notable institutional backers of CeriBell, Inc. include FMR, LLC, Fidelity, TPG GP A, LLC, according to Nexqual as of October 29, 2026 at 11:26 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 14.83% |
| Fidelity | 12.07% |
| TPG GP A, LLC | 9.8% |
| Red Tree Management, LLC | 5.75% |
| KCM Capital Inc | 2.93% |
| Federated Hermes, Inc. | 2.45% |
| Franklin Resources, Inc. | 2.39% |
| Adage Capital Partners GP L.L.C. | 2.35% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 5.04% |
| Vanguard Group | 2.95% |
Source: Nexqual, October 29, 2026 at 11:26 UTC.
From CeriBell, Inc.'s Latest SEC 10-K Filing (filed 2026-02-24)
Key Strengths & Strategy (as disclosed to the SEC)
- We intend to leverage our proprietary database of acute care EEG recordings and our data science and AI capabilities to identify patterns in EEG waveforms that may allow us to expand the use of the Ceribell System to other indications, both in the acute care setting and beyond.
- In December 2025, the FDA granted 510(k) clearance for our proprietary delirium monitoring solution, the first and only FDA cleared delirium detection and monitoring device.
- The Breakthrough Device Designation for LVO Stroke represents the latest achievement in Ceribell's continued efforts to extend its point-of-care EEG brain monitoring technology to additional indications, building on recent FDA 510(k) clearances for our next-generation Clarity® algorithm to detect electrographic seizures in pediatric patients (April 2025) and neonates (November 2025) and our proprietary delirium screening and monitoring solution (December 2025).
- Through our extensive database of EEG recordings and our data science and AI expertise, we have developed proprietary algorithms that power some of the most critical features of the Ceribell System by converting raw EEG waveforms into actionable clinical insights.
Legal & Regulatory Risks (Item 1A, quoted)
- The continued commercialization of our products depends in part on the extent to which governmental authorities and health insurers provide coverage and adequate reimbursement levels. Failure to obtain and maintain coverage and adequate reimbursement for our products could limit our ability to market those products and decrease our ability to generate revenue.
- We are subject to certain federal and state fraud and abuse laws and transparency laws, and any failure to comply could subject us to substantial penalties or other adverse consequences.
- Our employees, consultants and other commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements.
- We are exposed to the risk that our employees, consultants, and other commercial partners and business associates may engage in fraudulent or illegal activity.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| INSP | Inspire Medical Systems, Inc. | USD 70.97 | ▼ 0.46% |
| ESTA | Establishment Labs Holdings Inc | USD 68.97 | ▲ 3.02% |
| BFLY | Butterfly Network, Inc. | USD 7.81 | ▲ 5.83% |
| UFPT | UFP Technologies, Inc. | USD 286 | ▼ 3% |
| TMDX | TransMedics Group, Inc. | USD 66.9 | ▼ 4.06% |
| ALMR | Alamar Biosciences, Inc. | USD 34.3 | ▲ 7.42% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 11:26 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt